Skip to main content

Table 2 Pathology and treatment of patients undergoing pancreatic surgery before and during the COVID lockdown period

From: Pancreatic surgery during the COVID-19 pandemic 2020–2021: an observational cohort study from a third level referral center

  Before lockdown   
  2017/2018 2018/2019 2019/2020 Total Lockdown p value
Tumor localization (%)
Number 254 253 232 739 242  
Pancreas 200 (78.7) 219 (86.6) 179 (77.2) 598 (80.9) 197 (81.4) 0.925
Papilla 17 (6.7) 12 (4.7) 24 (10.3) 53 (7.2) 16 (6.6) 0.885
Common bile duct 10 (3.9) 10 (4.0) 12 (5.2) 32 (4.3) 13 (5.4) 0.483
Duodenum 27 (10.6) 12 (4.7) 17 (7.3) 56 (7.6) 16 (6.6) 0.672
Pathology (%)       
Adenocarcinoma 172 (85.0) 173 (68.4) 167 (72.0) 512 (69.3) 172 (71.1) 0.629
Neuroendocrine 19 (7.5) 19 (7.5) 12 (5.2) 50 (6.8) 19 (7.9) 0.564
Other malignancy 10 (3.9) 9 (3.6) 6 (2.5) 25 (3.4) 11 (4.6) 0.431  
IPMN 33 (13.0) 16 (6.3) 21 (9.1) 70 (9.5) 18 (7.4) 0.367  
Other benign 20 (7.9) 36 (14.2) 26 (11.2) 82 (11.1) 22 (9.1) 0.403
Tumor stage Adenocarcinoma (%)
0 3 (1.7) 4 (2.3) 3 (1.8) 17 (3.3) 2 (1.2) 0.186
1 8 (4.7) 23 (13.3) 27 (16.2) 79 (15.4) 23 (13.3) 0.716
2 73 (42.4) 52 (30.1) 54 (32.3) 183 (35.7) 53 (30.8) 0.387
3 66 (38.4) 63 (36.4) 67 (40.1) 205 (40.0) 83 (48.3) 0.061
4 22 (12.8) 31 (17.9) 16 (9.6) 70 (13.6) 23 (13.4) 0.999
Operation (%)       
Whipple 135 (53.2) 97 (38.3) 115 (49.6) 347 (47.0) 98 (40.5) 0.087
Total pancreatectomy 30 (11.8) 52 (20.6) 38 (16.4) 120 (16.2) 42 (17.4) 0.691
Distal Pancreatectomy 45 (17.7) 52 (20.6) 46a (19.8) 143 (19.4) 56b (23.1) 0.411
Exploration 44 (17.3) 52 (20.6) 33 (14.2) 129 (17.5) 46 (19.0) 0.876
Adjuvant chemotherapy adenocarcinomas (%) 117 (68.0) 132 (76.3) 118 (70.7) 367 (71.7) 125 (72.7) 0.263
  1. Patients operated by robotic surgery: a12, b26